目的 分析冠心丹参滴丸与替格瑞洛联合疗法在冠心病心绞痛方面的临床效果。方法 选取2023年1月—2024年6月淮南东方医院集团总医院收治的106例冠心病心绞痛患者病例资料进行回顾性分析，按治疗方法分成两组（各53例）。对照组口服替格瑞洛片，90 mg/次，2次/d。治疗组在对照组治疗基础上舌下含服冠心丹参滴丸，10粒/次，3次/d。观察两组患者临床疗效（心绞痛、心电图疗效），比较治疗前后两组患者心绞痛发作情况，心绞痛视觉模拟量表（VAS）、Duke和心绞痛生活质量问卷（APQLQ）评分，及血清细胞因子中性粒细胞与淋巴细胞比值（NLR）、红细胞压积（RDW）、血小板压积（PCT）和血小板分布密度（PDW）水平。结果 心绞痛疗效、心电图疗效的总有效率：治疗组（94.34%、88.68%）都高于对照组（81.13%、73.58%）（P＜0.05）。硝酸甘油用量、心绞痛发作持续时间和发作次数：治疗组都少于对照组（P＜0.05）。治疗后，两组心绞痛VAS、APQLQ评分及NLR、RDW、PCT、PDW水平均低于同组治疗前（P＜0.05），且治疗组变化幅度更甚（P＜0.05）。治疗后，两组Duke评分显著增加（P＜0.05），且治疗组变化幅度更甚（P＜0.05）。结论 冠心丹参滴丸联合替格瑞洛治疗冠心病心绞痛能有效抑制患者机体炎症反应，减少血栓形成，从而能进一步控制心绞痛发作、减轻疼痛，改善预后，促进患者生活质量改善。

Objective To analyze the clinical effect of Guanxin Danshen dropping pills combined with ticagrelor in the treatment of angina pectoris of coronary heart disease. Methods The clinical data of patients (106 cases) with angina pectoris in coronary heart disease in General Hospital of Huainan Oriental Hospital Group from January 2023 to June 2024 were analyzed retrospectively. According to the treatment method, they were divided into two groups (53 cases in each group). Patients in the control group were po administered with Ticagrelor Tablets, 90 mg/time, twice daily. Patients in the treatment group were sublingually administered with Guanxin Danshen Dripping Pills on the basis of the control group, 10 pills/time, three times daily. Patients in two groups were treated for 4 weeks. The clinical efficacy (angina pectoris, electrocardiogram) of the two groups were observed., and the angina attacks, VAS, Duke, and APQLQ scores for angina pectoris, and the levels of NLR, RDW, PCT, and PDW were compared between the two groups before and after treatment. Results The total effective rates of angina pectoris and electrocardiogram in the treatment group (94.34%, 88.68%)were higher than those in the control group (81.13%, 73.58%). The dosage of nitroglycerin, duration and frequency of angina pectoris attack in the treatment group were less than those in the control group (P < 0.05). After treatment, the angina VAS, APQLQ scores, NLR, RDW, PCT, and PDW levels in two groups were lower than those before treatment in the same group (P < 0.05), and the changes were more significant in the treatment group (P < 0.05). After treatment, a significant increase in the Duke score was observed in both groups (P < 0.05), and the changes were more significant in the treatment group (P < 0.05). Conclusion The combination treatment of coronary heart disease angina pectoris with Guanxin Danshen Dripping Pills and ticagrelor can effectively inhibit the patient's inflammatory response, reduce thrombus formation, further control angina attacks, alleviate pain, improve prognosis, and promote the improvement of the patient's quality of life.

R972

安徽省卫生健康委科研项目（AHWJ2021a037）